Subconjunctival bevacizumab injection for corneal neovascularization in recurrent pterygium
Subconjunctival bevacizumab injection for corneal neovascularization in recurrent pterygium
复制标题
DOI：
10.1080/02713680701799101
复制
发表时间：
2008-01-01
影响因子：
2
通讯作者：
Slomovic, Allan
中科院分区：
文献类型：
--
作者：
Bahar, Irit;Kaiserman, Igor;Slomovic, Allan
目的：我们报告了结膜下贝伐单抗对复发性翼状胬肉患者角膜血管密度的影响。研究方法：回顾性分析了5例复发性翼状胬肉患者的病历，这些患者接受了贝伐单抗（2.5 mg/0.1 ml）结膜下注射。眼科评价包括Snellen视力（VA）、眼压测量和注射前以及注射后1周、1个月和3个月的全面检查。通过图像分析软件分析眼睛的数码照片，以确定新血管覆盖的角膜面积占总角膜面积的百分比。结果：未观察到眼部或全身不良事件。注射后，在任何患者中均未观察到视力变化。一次贝伐珠单抗注射后角膜血管化的平均变化为0.03% +/- 0.45，而两次注射后的变化为0.025% +/- 0.19（均无统计学差异，t检验）。结论：短期结果表明，结膜下贝伐单抗耐受性良好，但不会导致复发性翼状胬肉的角膜血管消退。
Purpose: We report on the use of subconjunctival bevacizumab on corneal vessel density in recurrent pterygia. Methods: The charts of 5 patients with recurrent pterygium, who received subconjunctival injections of bevacizumab (2.5 mg/0.1 ml) were retrospectively reviewed. Ophthalmic evaluation included Snellen visual acuity (VA), tonometry and complete examination before the injection and at 1 week and 1 and 3 months thereafter. Digital photographs of the eyes were analyzed by image analysis software to determine the area of cornea covered by new vessels as a percentage of the total corneal area. Results: No ocular or systemic adverse events were observed. No change in visual acuity was noted in any patient following the injection. The mean change in corneal vascularization after one bevacizumab injection was 0.03% +/- 0.45, while after two injections the change was 0.025% +/- 0.19 (both not statistically different than zero, t-test). Conclusions: Short-term results suggest that subconjunctival bevacizumab is well tolerated but does not cause regression of corneal vessels in recurrent pterygium.